{"id":43503,"date":"2025-10-15T22:15:06","date_gmt":"2025-10-15T14:15:06","guid":{"rendered":"https:\/\/flcube.com\/?p=43503"},"modified":"2025-10-15T22:15:08","modified_gmt":"2025-10-15T14:15:08","slug":"livzon-launches-chinas-first-oral-gnrh-antagonist-for-multiple-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43503","title":{"rendered":"Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications"},"content":{"rendered":"\n

Livzon Pharmaceutical Group Inc. (HKG: 1513<\/a>), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.<\/p>\n\n\n\n

Market Potential and Development<\/strong>
Currently, no oral GnRH antagonist has been approved in China. Livzon plans to advance the development and commercialization of this Class 1 chemical new drug across Mainland China, Hong Kong, and Macao.<\/p>\n\n\n\n

Mechanism and Advantages<\/strong>
GnRH antagonists function by directly blocking pituitary GnRH receptors, inhibiting the synthesis and release of sex hormones. Key advantages include rapid onset, avoidance of hormonal “flare-up,” short treatment cycles, and quick recovery of pituitary function post-treatment.<\/p>\n\n\n\n

Innovation and Patient Compliance<\/strong>
Livzon’s oral GnRH antagonist stands out from existing injectable options, significantly improving patient compliance. Notably, no oral GnRH antagonist products have been launched in China, and globally, none exist for assisted reproduction indications.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the…<\/p>\n","protected":false},"author":1,"featured_media":43504,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1228,457],"class_list":["post-43503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-1513","tag-livzon-pharmaceutical"],"yoast_head":"\nLivzon Launches China's First Oral GnRH Antagonist for Multiple Indications - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43503\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications\" \/>\n<meta property=\"og:description\" content=\"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43503\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T14:15:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T14:15:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications\",\"datePublished\":\"2025-10-15T14:15:06+00:00\",\"dateModified\":\"2025-10-15T14:15:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503\"},\"wordCount\":164,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1504-1.webp\",\"keywords\":[\"HKG: 1513\",\"Livzon Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43503#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43503\",\"name\":\"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1504-1.webp\",\"datePublished\":\"2025-10-15T14:15:06+00:00\",\"dateModified\":\"2025-10-15T14:15:08+00:00\",\"description\":\"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43503\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1504-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1504-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43503#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications - Insight, China's Pharmaceutical Industry","description":"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43503","og_locale":"en_US","og_type":"article","og_title":"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications","og_description":"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.","og_url":"https:\/\/flcube.com\/?p=43503","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T14:15:06+00:00","article_modified_time":"2025-10-15T14:15:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43503#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43503"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications","datePublished":"2025-10-15T14:15:06+00:00","dateModified":"2025-10-15T14:15:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43503"},"wordCount":164,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43503#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","keywords":["HKG: 1513","Livzon Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43503#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43503","url":"https:\/\/flcube.com\/?p=43503","name":"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43503#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43503#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","datePublished":"2025-10-15T14:15:06+00:00","dateModified":"2025-10-15T14:15:08+00:00","description":"Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the successful introduction of an oral GnRH (Gonadotropin-Releasing Hormone) antagonist. This innovative drug covers several disease areas, including assisted reproduction, endometriosis, uterine fibroids, and prostate cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43503#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43503"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43503#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","width":1080,"height":608,"caption":"Livzon Launches China's First Oral GnRH Antagonist for Multiple Indications"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43503#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1504-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43503"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43503\/revisions"}],"predecessor-version":[{"id":43505,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43503\/revisions\/43505"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43504"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}